Chagas Disease in the Americas: Impacts and Opportunities for Control
|
|
- Terence Powell
- 5 years ago
- Views:
Transcription
1 Chagas Disease in the Americas: Impacts and Opportunities for Control Rick Tarleton Center for Tropical and Emerging Global Diseases University of Georgia The Chagas Disease Foundation
2 Trypanosoma cruzi and Chagas Disease the most neglected of the neglected diseases?
3 General Background 10 to 20 million infected worldwide - mostly (but not exclusively) in Latin America -poor surveillance limits the accuracy of estimates Transmission occurs by insect vector, food contamination, transplantation/transfusion and congenitally -none of these mechanism is especially efficient Diagnosis is usually decades after the initial infection and most do not receive treatment -Success of treatment is variable and/or difficult to assess -Adverse events Limited support for detection, prevention, treatment -diagnostics are poor -treatments are limited -vaccines are non-existent This is a zoonotic infection: it will not be eradicated
4 Situation outside of Latin America U.S. Southern U.S. is endemic although transmission to humans is low ~300,000 infected residents, most undiagnosed and untreated 70-80% (?) of donated blood screened; sensitivity of test is unknown other donated tissues are largely unscreened no licensed diagnostic test Physician awareness is very low Elsewhere Spain: ~50,000 infected immigrants rest of Europe, Canada, Australia, Japan (1,000 s each) limited screening and treatment capabilities in most countries Congenital and transfusion/transplantation associated transmission are largest concerns; poor monitoring and prevention
5 Immunity and Disease The vast majority of individuals infected with T. cruzi develop highly effective control of the infection but never clear the infection An effective treatment or preventative is going to have to do better than the normal immune response e.g. clear 100% of parasites Detection of infected individuals is difficult and detection of cure is even more difficult 5
6 Priority Issues for Chagas Disease: Development of better diagnostics Discovery, development and testing of better treatment regimens, including new drugs Better methods for assessing treatment efficacy Development of integrated, sustainable vector control protocols
7 Diagnosis of T. cruzi infection serological tests ELISA, IFA, IHA, CF Mostly with crude lysates or whole epimastigotes; a few with recombinant proteins Best 2 out of 3 detection (PCR) culture (xenodiagnosis or hemaculture)
8 Current serodiagnostics are inadequate Positive serology depends on the test. Results of random blood bank screening in Santa Cruz, Bolivia 8 Pirard, et al., 2005 Transfusion 45:
9 Seronegative subjects in endemic areas have T cell responses to T. cruzi 9 Olivera, et al Microbes and Inf.
10
11 10 insects per box; 40,640 total insects Cerisola, J.A PAHO Pub #347
12 PCR/Hemoculture results for confirmed seropostive U.S. blood donors + - % PCR (EDTA) Hemoculture (Heparin) Conclusion: PCR (or other parasite detection techniques) is not likely to be an effective method for diagnosis or for monitoring of treatment efficacy. Source: David Leiby, American Red Cross
13 Chemotherapeutics for Chagas disease Nifurtimox nitrofuran, appears to act by reduction of nitro groups to nitroanion radicals and consequently, reduced oxygen metabolites such as superoxide and peroxide Benznidazole a nitroimidazole that appears to induce reductive stress through the covalent modification of macromolecules by nitroreduction intermediates J. Urbina, Current Pharmaceutical Design, 2002
14 Chemotherapeutics for Chagas disease Dogma is that treatment is not effective unless given in the acute phase of infection Two drugs, nifurtimox and benznidazole, are capable of curing at least 50% of recent infections. These products are active in the acute and short-term (up to a few years) chronic phase. However, they have little or no activity in long-term chronic forms of the disease. WHO Problems -the definition of cure -what is accepted as proof of cure Absence of proof is not proof of absence
15 Efficacy of Benznidazole Treatment in Chronic Chagas disease Accessible tests of cure are needed in order to evaluate new therapies Viotti, et al Ann. Intern. Med. 144:
16 Chagas Disease: Vector Control Source: WHO/TDR
17
18
19
20 Short-comings of a vector control only approach: time-consuming, labor-intensive, never-ending insecticidal resistance is extensive distinct behavioral characteristics of various vector species
21 Opportunities: Diagnosis Almost certainly will have to depend on detection of immune responses rather than direct detection of parasites/products Tests do not need to be rapid point-of-care tests (testing can be centralized) Tests need to be rigorously certified and uniform (the format, e.g. ELISA, IFA, etc., is not the issue) single test without discordant or false negative outcomes preferably quantitative (for monitoring changes over time/post-treatment)
22 Assessing treatment efficacy this is the single biggest factor that prevents the utilization of existing drugs and the development of new drugs drug treatment in all acute and chronic cases is the only effective means of preventing the development of clinical disease direct parasite detection or detection of parasite products (proteins, DNA, etc.) is unlikely to satisfy this need development of a test that absolutely certifies parasitological cure is going to be difficult (but this is not unique to Chagas disease)
23 Pre-treatment Successful treatment Post-treatment Need: Cheaper platform
24 Can other biomarkers of cure be identified? Gene expression profiles Minning, et al., unpublished
25 Opportunities: Drug Development Much improved high and medium throughput screening assays have been developed - facilitates large (>1 million compounds) library screens -fast in vivo screens as follow-up Involvement of industry, PPP, non-profits in drug discovery (GSK, Novartis, Pfizer, Sanofi Aventis, DNDi, etc.) Needs: -Coordination and prioritization -post-screening financial support -follow-through -development/agreement on tools for assessment Chagas Drug Discovery Consortium 2 nd meeting Nov. 3, 2010, Atlanta, GA
26 Opportunities: Vector Control Vector control has been and can be highly effective in preventing transmission But vector control has to be more than simply spraying; insecticidal resistance is a big challenge One size does not fit all different characteristics of different environments Decisions/recommendations can not be based upon dogma, anecdotal evidence, or insufficient data Needs: Better use of simple tools and development of new tools Integration of methods for specific local situation Improved infrastructure for and commitment to supporting vector and transmission control
27 Example: Eliminate dogs as reservoirs of infectivity for reduviids Elimination of infected dogs from a household with infected people is nearly sufficient to extinguish transmission of T. cruzi, barring reintroduction of infected dogs, children, or bugs Cohen, et al., Science (2001) Strategy: Generate attentuated parasite lines by gene knockout Produce infective metacyclic trypomastigotes Deliver/vaccinate by oral administration Key Benefits: Vaccine does not have to provide 100% protection from infection just the prevention of development of a parasitemic infection cleared Neither the vaccine nor the challenge infection have to be completely Vaccine can be delivered rapidly to multiple animals
28 Summary: Drug therapy is the only option for the 20 million individuals already infected and for those who will become infected in the future. current treatments should be more widely used new therapies should be aggressively pursued Diagnostic assays to better protect against new infections and to assess the efficacy of treatment require development Integrating control efforts will require money, political will and local buy-in Policy Better articulation of the realistic opportunities Establishment of research and development priorities based upon rigorous and educated evaluations Development of mechanisms (funding) for improved and focused efforts in Chagas disease
. /////////////////// /////////////////// / Berenice? . BLOOD HEPATITIS B HEPATITIS C HIV T. pallidum T. cruzi TRANSFUSION HOST The Southern Cone Initiative, 1991 The Ministers of Health of Argentina,
More informationChagas Initiative. Chagas disease is one of the main public health problems in Latin America, where it is more common than malaria
Chagas Initiative Chagas Initiative The Chagas Initiative aims to increase access to effective diagnosis and treatment for patients with Chagas disease, both in endemic and non-endemic countries, and to
More informationChagas disease. (American trypanosomiasis)
Chagas disease (American trypanosomiasis) Epidemiology 7 to 8 million people worldwide are infected Endemic in Latin America and South America USA, Canada, Europe http://www.who.int/mediacentre/factsheets/fs340/en/index.html
More informationChagas Disease in non-endemic Countries
Chagas Disease in non-endemic Countries Tsutomu Takeuchi Institute of Tropical Medicine, Nagasaki University, Nagasaki Apparent distribution of Triatoma infestans 1983 2003 Migration flow of immigrants
More informationTrypanosomiasis WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Trypanosomiasis WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Disclaimer The views expressed in this presentation are those of the speaker and do not reflect the official policy
More informationWRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Trypanosomiasis WRAIR- GEIS 'Operational Clinical Infectious Disease' Course The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or
More informationCurrent Situation of Chagas Disease in Non-Endemic Countries
Current Research Topics in Tropical Diseases; Towards Successful Control and Elimination Juntendo Medical Journal 2015. 61 (4), 389-395 Current Situation of Chagas Disease in Non-Endemic Countries TAKESHI
More informationChagas disease: Challenges in Diagnostics
Chagas disease: Challenges in Diagnostics Emily Adams Royal Tropical Institute (KIT), KIT Biomedical Research The Netherlands e-mail: e.adams@kit.nl Aims of KIT Biomedical Research To contribute to the
More informationGHIT R&D Forum Session 4: Propelling R&D for late-stage projects
GHIT R&D Forum Session 4: Propelling R&D for late-stage projects Clinical Development of E1224 A New Treatment for Chagas Disease & Mycetoma Treatment, Fosravuconazole Clinical Trial Daisuke Imoto Head
More informationEDUCATIONAL COMMENTARY EMERGING INFECTIOUS DISEASE AGENTS
EDUCATIONAL COMMENTARY EMERGING INFECTIOUS DISEASE AGENTS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits
More informationTrypanosomiasis. By Ahmed Faris Alila Ahmed Laith Al-Nuaimi Ahmed Mohammed Al-juboory Ahmed Naaif Talib Ahmed Nadhem Al-Obeidy Osama Ahmed Al-Obeidy
Trypanosomiasis By Ahmed Faris Alila Ahmed Laith Al-Nuaimi Ahmed Mohammed Al-juboory Ahmed Naaif Talib Ahmed Nadhem Al-Obeidy Osama Ahmed Al-Obeidy Ahmed Faris Alila Trypanosomiasis Kingdom: Protisata
More informationTrypanosomiasis. Introduction. Epidemiology. Global Epidemiology. Trypanosomiasis Risk in UK Travellers
Trypanosomiasis Introduction Epidemiology Risk for travellers Transmission Signs and symptoms Treatment Prevention References Reading list Links Introduction Trypanosomiasis is caused by parasitic protozoa
More informationLEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS
FACT SHEET LEADING DENGUE VACCINE CANDIDATE COULD CHANGE THE LIVES OF MILLIONS A GLOBAL PUBLIC HEALTH CHALLENGE Dengue fever, a mosquito-borne disease caused by four types of dengue viruses, is a threat
More informationTrypanosoma cruzi Parasitemia in US Blood Donors with Serologic Evidence of Infection
BRIEF REPORT Trypanosoma cruzi Parasitemia in US Blood Donors with Serologic Evidence of Infection David A. Leiby, 1 Ross M. Herron, Jr., 2 George Garratty, 2 and Barbara L. Herwaldt 3 1 Transmissible
More informationUsefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations
122 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 104(Suppl. I): 122-135, 2009 Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations Constança Carvalho
More informationBMGF MALARIA STRATEGY TO 2020
BMGF MALARIA STRATEGY TO 2020 Supporting the Drive to Elimination in Mesoamerica & Hispaniola Diana Measham, DrPH, MSc Lead Eliminate Initiative September 25, 2014 The world has three potential future
More informationCriteria of Chagas Disease Cure
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 94, Suppl. I: 331-335, 1999 331 Criteria of Chagas Disease Cure J Romeu Cançado Cadeira de Terapêutica Clínica, Universidade Federal de Minas Gerais, Caixa Postal
More informationAnswering your daily challenges. in the ELISA technology I N FECTI OUS DISEASES. bioelisa
Answering your daily challenges in the ELISA technology I N FECTI OUS DISEASES bioelisa RETROVIRUS HIV is the cause of the most important global pandemic. Due to the lack of vaccination, early diagnosis
More informationDonor-Derived Trypanosoma cruzi Infection in Solid Organ Recipients in the United States,
American Journal of Transplantation 2013; XX: 1 8 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12340
More informationNeglecting Diseases. Jason Silverstein Department of Anthropology Harvard University
Neglecting Diseases Jason Silverstein Department of Anthropology Harvard University I will give you a talisman. Whenever you are in doubt or when the self becomes too much with you, apply the following
More informationTechnical Advisor. JICA Nicaragua Chagas Disease Control Project Nicaragua
Kota Yoshioka is currently working as technical advisor for Chagas disease control project which isrun by Japan International Cooperation Agency (JICA) and the Ministry of Health of Nicaragua (2009-2014).
More informationRESEARCH ON AIDS IN LATIN AMERICA AND THE CARIBBEAN
ACHR 29/93.10 Original: Spanish RESEARCH ON AIDS IN LATIN AMERICA AND THE CARIBBEAN Division of Communicable Diseases Prevention and Control Program of AIDS and Sexually Transmitted Diseases July 1993.1..
More informationNeglected Diseases (NDs) Landscape in Brazil and South America
Frontiers in Science on Neglected Diseases 13 th November 2014 Neglected Diseases (NDs) Landscape in Brazil and South America Jeffrey Shaw São Paulo University Biomedical Sciences Institute jeffreyj@usp.br
More informationSTRATEGY FOR NEGLECTED TROPICAL DISEASES
STRATEGY FOR NEGLECTED TROPICAL DISEASES 2015-2020 1 ABOUT FIND FIND was established in 2003 to bridge existing development gaps for essential diagnostics by initiating and coordinating research and development
More informationViral Hepatitis B and C in North African Countries
Viral Hepatitis B and C in North African Countries Prevalence, Risk factors and How to prevent Prof. Ossama Rasslan President, ESIC ICAN, Vice-Chair ICAN 2014, Harare, Zimbabwe, Nov 3rd 5th Overview Viral
More informationThe Application of Latent Class Analysis for Diagnostic Test Validation of Chronic Trypanosoma cruzi Infection in Blood Donors
BJID 2002; 6 (August) 181 The Application of Latent Class Analysis for Diagnostic Test Validation of Chronic Trypanosoma cruzi Infection in Blood Donors Dante M. Langhi Junior, José O. Bordin, Adauto Castelo,
More informationHow has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH
How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH Presentation Outline Big history of global HIV epidemic Current status of HIV and the global AIDS
More informationDonation Criteria for Men who have Sex with Men (MSM): Update from Canadian Blood Services
Donation Criteria for Men who have Sex with Men (MSM): Update from Canadian Blood Services Outline 1 Current criteria Proposed criteria Stakeholder outreach Outline 2 Safety Assessment Results since implementation
More informationnewsletter Chagas Invest in R&D to deliver improved treatments Target Product Profile for Chagas disease CHAGAS disease in short
Chagas The Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit product development partnership working to research and develop new and improved treatments for neglected diseases
More informationNEWS BK NEWS # 378 /MKT DATE : TITLE. Dear colleagues,
1 NEWS BK NEWS # 378 /MKT DATE : 16022016 TITLE : New Bioelisa reagents Brochures Dear colleagues, We are pleased to present the new Bioelisa reagents Brochures, which are a very useful marketing and selling
More informationHEALTHCARE IN THE DEVELOPING WORLD - THE ROLE OF INTELLECTUAL PROPERTY. ODI: 12 February 2003
HEALTHCARE IN THE DEVELOPING WORLD - THE ROLE OF INTELLECTUAL PROPERTY ODI: 12 February 2003 KEY QUESTIONS What role does IP play in the development of new drugs and vaccines for the developing world?
More informationGlobal Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today
Global Pandemic Preparedness Research Efforts Klaus Stöhr 3 Today Medium-term applied research linked to medical and public health interventions addressing the current pandemic situation in Asia Natural
More informationBabesia from a donor perspective
Babesia from a donor perspective American Red Cross, Massachusetts Region Bryan Spencer, MPH Research Scientist American Society for Apheresis Annual Meeting May 8, 2015 San Antonio, TX The need is constant.
More informationProtozoa from tissues. Leishmania spp. Naegleria fowleri Toxoplasma gondii Trichomonas vaginalis Trypanosoma spp.
Protozoa from tissues Leishmania spp. Naegleria fowleri Toxoplasma gondii Trichomonas vaginalis Trypanosoma spp. Leishmaniasis Leishmania infantum, Leishmania donovani, in macrophages of man. Female sandflies:
More informationEmerging TTIs How Singapore secure its blood supply
Emerging TTIs How Singapore secure its blood supply Ms Sally Lam Acting Division Director I Blood Supply Management I Blood Services Group I Health Sciences Outline Risk Mitigation Strategies to secure
More informationFISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated ) USAID Global Health Programs (GHP) and State Department
FISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated 2.13.19) Contact: Brian Massa, Senior Manager for Global Health Advocacy, Shot@Life (bmassa@unfoundation.org) USAID Global Health Programs (GHP) and State
More informationWorld Health Organization Department of Communicable Disease Surveillance and Response
WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases World Health Organization Department of Communicable Disease Surveillance and Response This document has been downloaded from the
More informationBLOOD DONORS AND BLOOD COLLECTION
Blackwell Publishing IncMalden, USATRFTransfusion41-113226 American Association of Blood BanksOctober 2646117371744Original ArticleNew assay for T. Cruzi artibodies on a fully automated analyzerchang ET
More informationHAEMOFLAGELLATES. Dr. Anuluck Junkum Department of Parasitology Faculty of Medicine
HAEMOFLAGELLATES Dr. Anuluck Junkum Department of Parasitology Faculty of Medicine Objective Can describe the morphology, life cycle, pathology, diagnosis and prevention of Leishmania spp. and Trypanosoma
More informationLancet. 2010;375(9723):
Lancet. 2010;375(9723):1388-402 Lancet. 2010;375(9723):1388-402 Fundação)Pro,Sangue)Results)(1993,94)) Tests% N% %% IFA$ 2,809$ 40.5$ IHA$ 902$ 13.0$ ELISA$ 541$ 7.8$ IFA$+IHA$ 215$ 3.1$ IFA$+EIA$ 277$
More informationRoadmaps as a Vehicle for Addressing Large- Scale Public Health Challenges: Lessons from the Malaria Vaccine Technology Roadmap
Background to development of vaccine roadmaps, to include priority areas for research, product development, capacities, and policy and commercialization Roadmaps as a Vehicle for Addressing Large- Scale
More informationThe Global Movement to Eliminate Viral Hepatitis. John W Ward, MD Task Force for Global Health CDC, Atlanta, Georgia, USA
The Global Movement to Eliminate Viral Hepatitis John W Ward, MD Task Force for Global Health CDC, Atlanta, Georgia, USA Infection and Disease Control, Elimination and Eradication Control Below acceptable
More informationEPIDEMIOLOGICAL SURVEILLANCE REPORT Malaria in Greece, 2017, up to 17/08/2017
Page 1 EPIDEMIOLOGICAL SURVEILLANCE REPORT Malaria in Greece, 2017, up to 17/08/2017 Introduction Greece was declared free from malaria in 1974, following an intense control program (1946-1960). Since
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More informationViral Hepatitis Prevention Board CREATIVE FINANCING SOLUTIONS TO SCALE UP PREVENTION & TREATMENT OF HBV/HCV
Viral Hepatitis Prevention Board CREATIVE FINANCING SOLUTIONS TO SCALE UP PREVENTION & TREATMENT OF HBV/HCV vhpt-booklet-edits.indd 1 PUBLIC HEALTH TARGET WHO TARGETS TO CONTROL VIRAL HEPATITIS BY 2030
More informationREPORT INFORMAL CONSULTATION ON CHAGAS DISEASE IN THE WESTERN PACIFIC
Meeting Report Informal Consultation on Chagas Disease in the Western Pacific Nagasaki, Japan 29 30 June 2011 REPORT INFORMAL CONSULTATION ON CHAGAS DISEASE IN THE WESTERN PACIFIC Convened by: WORLD HEALTH
More informationNeglected Tropical Diseases
Neglected Tropical Diseases 26-27 Achievements 28 Challenges Dr Lorenzo Savioli Director The Neglected Tropical Disease extended family Lymphatic filariasis Onchocerciasis Schistosomiasis Soil-transmitted
More informationSummary World Malaria Report 2010
Summary The summarizes information received from 106 malaria-endemic countries and other partners and updates the analyses presented in the 2009 Report. It highlights continued progress made towards meeting
More informationPOSSIBLE RESPONSES TO 12 COMMON ARGUMENTS AGAINST THE FCTC
POSSIBLE RESPONSES TO 12 COMMON ARGUMENTS AGAINST THE FCTC 1. Signing and ratifying the FCTC is a long and complicated process it will take government a long time. If there is sufficient political will,
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationWe are pleased to present the new Leaflet bioelisa Menu and Instrumentation, with reference
NEWS BK NEWS# 390/ MKT DATE : 13-07-2016 TITLE : New Leaflet bioelisa Menu and Instrumentation Dear colleagues, We are pleased to present the new Leaflet bioelisa Menu and Instrumentation, with reference
More informationA Briefing Paper on Rotavirus
COMMON VIRUS AND SENSELESS KILLER: A Briefing Paper on Rotavirus DIARRHEA KILLS. MOTHERS IN THE WORLD S POOREST COUNTRIES KNOW THIS ALL TOO WELL. It s a fact few people in wealthier nations realize. Rotavirus
More informationReducing Babesia and Malaria Risks: Testing, Donor Selection, Inactivation. Susan L. Stramer PhD IPFA 23 rd Meeting May
Reducing Babesia and Malaria Risks: Testing, Donor Selection, Inactivation Susan L. Stramer PhD IPFA 23 rd Meeting May 26 2016 Babesiosis Malaria-like illness caused by babesia spp. Asymptomatic fatal
More informationFact sheet. Yellow fever
Fact sheet Key facts is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow in the name refers to the jaundice that affects some patients. Up to 50% of severely affected
More informationThe Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
More informationOIE/FAO Global Conference on foot and mouth disease. The way towards global control. Paraguay: 24 to 26 June Draft Resolution version 8
OIE/FAO Global Conference on foot and mouth disease The way towards global control Paraguay: 24 to 26 June 2009 Draft Resolution version 8 Considering that: Foot and mouth disease (FMD) has for centuries
More informationYellow fever. Key facts
From: http://www.who.int/en/news-room/fact-sheets/detail/yellow-fever WHO/E. Soteras Jalil Yellow fever 14 March 2018 Key facts Yellow fever is an acute viral haemorrhagic disease transmitted by infected
More informationParasitic Protozoa, Helminths, and Arthropod Vectors
PowerPoint Lecture Slides for MICROBIOLOGY ROBERT W. BAUMAN Chapter 23 Parasitic Protozoa, Helminths, and Arthropod Vectors Parasitic Diseases Protozoan and helminthic parasites are emerging as serious
More informationDriving access to medicine
Driving access to medicine An example from the Novartis Malaria Initiative Hans Rietveld Director, Market Access & Capacity Building Novartis Malaria Initiative Social Forum - Geneva February 20, 2015
More informationAssessing economic vulnerability to emerging infectious disease outbreaks: Ebola versus Zika
Assessing economic vulnerability to emerging infectious disease outbreaks: Ebola versus Zika Dr Anas El Turabi National Academy of Medicine Forum on Antimicrobial Threats June 12, 2018 The ultimate goal
More informationUpdate on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009
Update on A(H1N1) pandemic and seasonal vaccine availability July 7, 2009 Presentation objectives and approach Presentation Objectives Review production status for 2009-2010 Northern Hemisphere vaccine
More informationSummary of the Meeting of the Strategic Advisory Group of Experts on immunization, April 2018
Summary of the Meeting of the Strategic Advisory Group of Experts on immunization, 17-18 April 2018 The Strategic Advisory Group of Experts (SAGE) on Immunization 1 met on 17 18 April 2018. This full report
More informationRepellent Soap. The Jojoo Mosquito. Africa s innovative solution to Malaria prevention. Sapphire Trading Company Ltd
The Jojoo Mosquito Repellent Soap Africa s innovative solution to Malaria prevention Sapphire Trading Company Ltd P.O.Box: 45938-00100 Nairobi, Kenya. Tel: +254 735 397 267 +254 733 540 868 +254 700 550
More informationRole of vaccination and the evaluation of LSD control programmes
Role of vaccination and the evaluation of LSD control programmes Dr Nick Lyons FAO Workshop: LSD prevention and control Tbilisi, Georgia, 11th November 2015 Vaccines and protection Susceptible Infected
More informationاعداد رغداحمد رغد جمال الدين
اعداد رغداحمد رغد جمال الدين Trypanosoma Causes Trypanosomiasis West African Trypanosomiasis T.brucei gambiense Sleeping sickness East African Trypanosomiasis T.brucei rhodesiense American Trypanosomiasis
More informationRecommendations for Coping with Leishmaniasis: A Review of Control Strategies. Centro de Convenções de Reboças Red Room 17: 00h
Recommendations for Coping with Leishmaniasis: A Review of Control Strategies Centro de Convenções de Reboças 08.04.2014 Red Room 17: 00h Leishmaniasis - a Global Problem Visceral 2012 300 000 cases 20,000
More informationCommon Virus and Senseless Killer: A Briefing Paper on Rotavirus
Common Virus and Senseless Killer: A Briefing Paper on Rotavirus Diarrhea kills. Mothers in the world s poorest countries know this all too well. It s a fact few people in wealthier nations realize. Rotavirus
More informationSituation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011
Situation of XMRV and Blood Transfusion Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Lombardi et al. Science 326, 585 (2009) Conclusions: CFS and XMRV XMRV found in 67% of CFS patients
More informationMalaria DR. AFNAN YOUNIS
Malaria DR. AFNAN YOUNIS Objectives: Epidemiology of malaria Clinical picture Mode of transmission Risk factors Prevention and control Malaria is a life-threatening disease caused by Plasmodium parasites
More informationFact sheet. Poliomyelitis. WHO Media centre. ADAPTED FOR ADDITION TO THE RHIZOME POLIOK.IT PLATFORM 16 Jan 2017 INFORMATION FOR ERADICATION FROM
Fact sheet Poliomyelitis WHO Media centre ADAPTED FOR ADDITION TO THE RHIZOME POLIOK.IT PLATFORM 16 Jan 2017 INFORMATION FOR ERADICATION FROM Media centre Poliomyelitis Fact sheet Updated April 2016 Key
More informationOnly one take home point for the talk 9/26/2018. Infectious Diseases and Donor Derived Infections. Don t forget about donor-derived infections
Shane Colombo 1993 2018 Infectious Diseases and Donor Derived Infections Peter Chin-Hong, MD Division of Infectious Diseases UCSF Only one take home point for the talk Don t forget about donor-derived
More informationChagas Ab. Principle of the Test. Introduction. Figure 1. Principle of the Test
Code: 60481002 Chagas Ab Format: 3 x 12 tests For In vitro Diagnostic Use only Intended Use The ImmunoComb II Chagas Ab Kit is a rapid test intended for the qualitative detection of total antibodies to
More informationKINETOPLASTIDS. Kinetoplast. Nucleus
KINETOPLASTIDS Kinetoplast Nucleus widespread parasites animals (fish humans) insects plants monophyletic group related to euglenoids unifying feature = kinetoplast Giemsa staining structure KINETOPLAST
More informationFINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA
Comprehensive Family Immunization Family and Community Health Area FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES 24-26 AUGUST 2009, COSTA RICA Epidemiological
More informationEPIDEMIOLOGICAL SURVEILLANCE REPORT Malaria in Greece, 2018, up to 22/10/2018
Page 1 EPIDEMIOLOGICAL SURVEILLANCE REPORT Malaria in Greece, 2018, up to 22/10/2018 Introduction Greece was declared free from malaria in 1974, following an intense control program (1946-1960). Since
More informationEC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
More informationCongenital CMV infection. Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara
Congenital CMV infection Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara Congenital CMV infection Approximately 0.15 2% of live births
More informationD.A.Henderson, MD, MPH. Professor of Medicine, University of Pittsburgh Honorary Fellow, London School of Hygiene and Tropical Medicine
Polio Eradication a reconsideration of strategy D.A.Henderson, MD, MPH Professor of Medicine, University of Pittsburgh Honorary Fellow, London School of Hygiene and Tropical Medicine Baltimore, Maryland
More informationCenter for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home
Center for Global Health CDC Global Health Saving Lives Overseas, Protecting Americans at Home CDC Overview Part of the U.S. Department of Health and Human Services, CDC is the nation s leading public
More informationAOHS Global Health. Unit 1, Lesson 3. Communicable Disease
AOHS Global Health Unit 1, Lesson 3 Communicable Disease Copyright 2012 2016 NAF. All rights reserved. A communicable disease is passed from one infected person to another The range of communicable diseases
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationPartnering to tackle Neglected Tropical Diseases
Partnering to tackle Neglected Tropical Diseases 2013 IEEE Global Humanitarian Technology Conference Tala de los Santos Diagnostics Group Leader 21 October 2013 NEGLECTED TROPICAL DISEASES The most important
More informationJune 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
June 8, 2018 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA 2016 D 0545,
More informationEradication of poliomyelitis
EXECUTIVE BOARD EB142/37 142nd session 27 November 2017 Provisional agenda item 6.4 Eradication of poliomyelitis 1. This report provides an update on the status of the four objectives of the Polio Eradication
More informationOrgan Transplantation Market Research Report- Global Forecast Till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR
More informationRisk of Other Donor-Derived Infections (nonhiv, nonhcv) Daniel Kaul MD Associate Professor University of Michigan
Risk of Other Donor-Derived Infections (nonhiv, nonhcv) Daniel Kaul MD Associate Professor University of Michigan Conflict of Interest Disclosure I have no relevant financial relationships to disclose
More informationBackground. Proposed to develop a framework for action. Address by Foreign Minister Koumura
July 2008 Ministry of Foreign Affairs of Japan Background Address by Foreign Minister Koumura Global Health and Japan s Foreign Policy From Okinawa to Toyako (25 November 2007) Special Address by Prime
More informationWHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections
Common structure Universal Health Coverage SDGs Cascade of services Vision, Goals and Targets Costed Actions WHO Global Health Sector Strategies 2016-2021 HIV; Viral Hepatitis; Sexually Transmitted Infections
More informationFact sheets on sustainable development goals: health targets. Malaria
SDG target 3.3: by 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, waterborne diseases and other communicable diseases. Fact sheets on sustainable
More informationFIRST MEETING OF THE TECHNICAL ADVISORY GROUP ON PUBLIC HEALTH ENTOMOLOGY PAN AMERICAN HEALTH ORGANIZATION
SUMMARY FIRST MEETING OF THE TECHNICAL ADVISORY GROUP ON PUBLIC HEALTH ENTOMOLOGY PAN AMERICAN HEALTH ORGANIZATION The first meeting of the Technical Advisory Group on Public Health Entomology (TAG PHE),
More informationRecollections of Ruth and Victor Nussenzweig. ( both MD.PhD, Professors at New York University School of Medicine)
1 of 5 9/27/2010 8:55 PM Recollections of Ruth and Victor Nussenzweig ( both MD.PhD, Professors at New York University School of Medicine) Ruth and I are happy to describe the very beginning of our scientific
More informationKinetoplastids Handout
Kinetoplastids Handout 1 Kinetoplastids widespread group of flagellated protozoa parasitize virtually all animal groups as well as plants and insects 3 distinct kinetoplastid species cause human disease
More informationStrategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
Expert Review of Anti-infective Therapy ISSN: 1478-7210 (Print) 1744-8336 (Online) Journal homepage: https://www.tandfonline.com/loi/ierz20 Strategies to enhance access to diagnosis and treatment for Chagas
More informationTrypanosoma cruzi, the etiologic agent of Chagas
ORIGINAL RESEARCH Frequency of Trypanosoma cruzi parasitemia among infected blood donors with a potential association between parasite lineage and transfusion transmission David A. Leiby, 1 * Megan L.
More informationCHAGAS DISEASE: A Latin American Nemesis
CHAGAS DISEASE: A Latin American Nemesis The following report was prepared by the Institute for OneWorld Health as part of a grant donated by the Bill and Melinda Gates Foundation. The purpose of this
More informationRunning Head: VECTOR-BORNE DISEASES: MALARIA IN CHILDREN 1
Running Head: VECTOR-BORNE DISEASES: MALARIA IN CHILDREN 1 Vector-Borne Disease: Malaria in Children Tabitha J. Long George Mason University GCH 360_002: Health and Environment Due: May 6, 2015 Running
More informationMarta de Lana 1 and Olindo Assis Martins-Filho Introduction
BioMed Research International Volume 2015, Article ID 652985, 10 pages http://dx.doi.org/10.1155/2015/652985 Review Article Revisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New
More information2014 Towards an HIV Cure symposium Melbourne The Role of a Public-Private Partnership in HIV Cure
2014 Towards an HIV Cure symposium Melbourne The Role of a Public-Private Partnership in HIV Cure Mike McCune, MD, PhD University of California, San Francisco Cure Interventions that Can Be Used Around
More informationChallenges for viral hepatitis prevention in Latin American
Challenges for viral hepatitis prevention in Latin American One in three people on earth has been exposed to hepatitis B or C viruses (HBV and HCV); HBV and HCV are responsible for 57% of cirrhosis and
More informationFDA Reentry Guidance
FDA Reentry Guidance T. cruzi - Chagas, Hepatitis C and HIV Wednesday 6/6/18 Doug Denyer O Dina Hurlburt, SBB(ASCP)CM Outline Impact to Clients Review of FDA Guidance Documents Reentry Request Process
More information